Ai Luming's defense lawyer recently disclosed that the founder of Wuhan Dangdai Group and Humanwell Healthcare was criminally detained on July 8 for suspected illegal absorption of public deposits. This marks the judicial accountability phase of the "Dangdai System" capital crisis, which once commanded assets worth billions, and prompts a market re-evaluation of the multiple governance, financial, and compliance risks accumulated under Humanwell Healthcare's former controlling shareholder.
Aggressive Expansion Creates Three Core Underlying Risks
Humanwell Healthcare originated from a graduate entrepreneurial team at Wuhan University in 1988. After securing a rare license to produce narcotics in 2001, it became a domestic leader in analgesic drugs. However, the diversified expansion led by controlling shareholder Ai Luming planted systemic risks. First, there is the risk of disorderly diversification and high-leverage debt. Dangdai Group aggressively invested in non-core sectors like real estate, cultural tourism, finance, and sports copyrights. Industrial profits could not cover financing costs, and the group's interest-bearing debt ballooned, relying on a "borrow new to repay old" model, creating a fragile capital chain of short-term borrowing for long-term investment. The 2022 bond default triggered a liquidity crisis, with widespread defaults on its wealth management platforms, directly leading to the criminal investigation for illegal fundraising. Second, listed company funds were maliciously siphoned. Regulatory investigations confirmed that from 2020 to March 2022, Dangdai Group non-operationally occupied 12.785 billion yuan from Humanwell Healthcare. This was achieved through third-party transactions, with a "year-end return, re-occupation next year" pattern, peaking at over 8 billion yuan in a single year, severely eroding the listed company's operating cash flow and development funds. Third, securities compliance was fully compromised. Beyond the massive fund occupation, the company also engaged in profit inflation, concealing related-party relationships, failing to disclose related-party transactions, and making false records and material omissions in periodic reports. Dangdai Group, using its shareholder status in Tianfeng Securities, illegally borrowed billions of yuan without any disclosure obligations. Ai Luming received seven-year and lifetime market bans, with total fines nearing 9 million yuan. With multiple violations compounding, Humanwell Healthcare was placed under investigation by the CSRC in 2024, received an administrative penalty notice in late 2025, and was designated as a special treatment (ST) risk warning stock, with daily price fluctuation limits narrowed to 5%, restricting public market financing channels.
Restructuring and Change of Control, Yet Historical Burdens Remain Unresolved
After the debt crisis, creditors applied to the Wuhan Intermediate Court for Dangdai Group's restructuring in September 2024. The restructuring plan was approved in April 2025, with China Merchants Group acquiring 23.70% of Humanwell Healthcare's shares through judicial transfer, becoming the new controlling shareholder and starting a central enterprise integration phase. However, risks from the old era continue to weigh on the company. First, there is market confidence and valuation pressure. Although occupied funds and interest have been fully repaid and internal controls rectified, the ST designation remains, dampening institutional allocation willingness. The stock is passively excluded from indices, and financing costs and bank credit lines are under pressure, creating short-term capital turnover strain. Second, asset disposal and growth momentum are insufficient. Since China Merchants Group took over, a refocusing strategy has been implemented, divesting non-core assets like maternal and infant products, medical supplies, and Lifestyles (parent of Jissbon). Resources are concentrating on the core narcotics business, but the company's 2025 revenue fell 5.79% year-on-year. Profit growth is heavily reliant on cost-cutting and asset disposal gains, with new drug pipeline progress and market expansion at a slower pace, raising doubts about sustainable endogenous growth. Third, the criminal proceedings against the former controlling shareholder introduce uncertainty. Ai Luming's case is still under investigation, with related funds, transactions, and historical guarantees awaiting judicial clarification. This could lead to subsequent events like related lawsuits, debt recovery, and asset verification, continuously disrupting corporate governance and goodwill.
Governance Restructuring is Key to Mitigating Risks
The root of this crisis lies in the private controlling shareholder treating the listed company as a personal cash pool, lacking independent and effective internal controls and checks and balances. After China Merchants Group took over, the board was restructured, and a central enterprise risk control system was fully implemented, institutionally preventing major shareholder encroachment. However, long-term risk resolution requires three tasks. First, continuously improve internal controls and information disclosure systems, conduct regular and full-process checks on funds and related-party transactions to prevent historical issues like fund occupation and non-disclosure, and quickly meet the conditions for removing the ST label to restore capital market financing functions. Second, focus on the core narcotics business by increasing R&D investment, leveraging central enterprise resources to expand into sub-segments like severe illness and cancer pain, and shift from a profit structure reliant on asset sales to a solid long-term performance foundation. Third, closely monitor the progress of Ai Luming's criminal case, promptly disclose any litigation or debt-related matters that may affect the company, fully protect minority investors' right to know, and gradually rebuild market trust. Ai Luming's detention is a powerful market accountability measure for the former controlling shareholder's irregular capital operations. It also serves as a warning for Humanwell Healthcare: high-quality pharmaceutical assets, if detached from standardized governance and prudent financial discipline, can easily fall into a dual trap of debt and compliance issues. For the current ST Humanwell Healthcare, state-owned asset integration is only the starting point for risk resolution. Only by addressing historical governance flaws and rebuilding sustainable core business growth can it completely emerge from the shadow of the "Dangdai System."
Comments